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OBJECTIVE— The albumin-to-creatinine ratio (ACR) reflects urinary albumin excretion and
is increasingly being accepted as an important clinical outcome predictor. Because of the great
public health need for a simple and inexpensive test to identify individuals at high risk for
developing type 2 diabetes, it has been suggested that the ACR might serve this purpose. We
therefore determined whether the ACR could predict incident diabetes in a well-characterized
cohort of pre-diabetic Americans.
RESEARCH DESIGN AND METHODS— A total of 3,188 Diabetes Prevention Pro-
gram (DPP) participants with a mean BMI of 34 kg/m2 and elevated fasting glucose, impaired
glucose tolerance, and baseline urinary albumin excretion measurements were followed for
incident diabetes over a mean of 3.2 years.
RESULTS— Of the participants, 94% manifested ACR levels below the microalbuminuria
range and 21% ultimately developed diabetes during follow-up. Quartiles of ACR (median
[range] within quartiles: 1, 3.0 [0.7–3.7]; 2, 4.6 [3.7–5.5]; 3, 7.1 [5.5–9.7]; and 4, 16.5 [9.7–
1,578]) were positively associated with age, markers of adiposity and insulin secretion and
resistance, blood pressure, and use of antihypertensive agents with antiproteinuric effects and
inversely related to male sex and serum creatinine. An elevated hazard rate for developing
diabetes with doubling of ACR disappeared after adjustment for covariates. Within the DPP
intervention groups (placebo, lifestyle, and metformin), we found no consistent trend in incident
diabetes by quartile or decile of ACR.
CONCLUSIONS— An ACR at levels below the microalbuminuria range does not indepen-
dently predict incident diabetes in adults at high risk of developing type 2 diabetes.
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W ith the explosive growth of inci-dent diabetes, type 2 diabeteshas become a major interna-
tional public health challenge. Moreover,
an increasing number of individuals have
evidence of a pre-diabetic state, which in-
dicates significant future risk of develop-
ing diabetes. Fortunately, accumulating
evidence suggests that type 2 diabetes can
be delayed or prevented in individuals
with pre-diabetes by either lifestyle mod-
ification or medication (1–2). However,
because prevention is a fundamental pub-
lic health goal, there is clearly a great need
for effective strategies to identify high-risk
individuals. Unfortunately, the best avail-
able risk stratification method is an oral
glucose tolerance test (OGTT), which is
both costly and difficult to perform in a
clinical setting.
The albumin-to-creatinine ratio
(ACR) in a single untimed urinary speci-
men is a reflection of urinary albumin ex-
cretion and is increasingly being accepted
as a marker that predicts several impor-
tant health outcomes, including hyper-
tension, kidney failure, cardiovascular
events, and mortality (3–5). These associ-
ations have been observed throughout the
biological range, even at levels far below
those previously considered to be patho-
logical (e.g., microalbuminuria) (6).
The ACR is also closely linked to car-
diometabolic risk factors, vascular dis-
ease, and insulin resistance (7–9) and
might therefore play a clinically impor-
tant role in predicting future onset of di-
abetes. Observational studies have shown
an association between ACR and other
markers of urinary albumin excretion and
incident diabetes (10–12). In addition,
observations that proteinuria-reducing
therapies (e.g., ACE inhibitors and angio-
tensin II receptor blockers) delay progres-
sion to diabetes also support this
hypothesis, albeit indirectly (13,14).
However, the observational studies were
heterogeneous in terms of study design
and risk for incident diabetes, did not in-
clude proteinuria throughout its biologic
range, and/or recruited individuals from
ethnic groups distinct from the general
U.S. population. In addition, a random-
ized clinical trial did not find that
ramipril, a proteinuria-reducing agent, al-
tered the incidence of diabetes (15).
The Diabetes Prevention Program
(DPP) enrolled a large and well-
characterized cohort of adults who were
at high-risk for developing diabetes based
on having elevated fasting glucose and
impaired glucose tolerance. We tested the
hypothesis that ACR, throughout its bio-
logical range, improves the prediction of
future diabetes.
RESEARCH DESIGN AND
METHODS— The eligibility criteria,
design, and methods of the DPP have
been reported elsewhere (16). In brief, el-
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igibility criteria included age 25 years,
BMI 24 kg/m2 (22 kg/m2 in Asian
Americans), and fasting plasma glucose
levels between 95 and 125 mg/dl (lower
limit did not apply to the American Indian
centers) in addition to impaired glucose
tolerance (IGT) by an oral glucose toler-
ance test (OGTT) (plasma glucose of
140–199 mg/dl 2 h after a 75-g oral glu-
cose load). Participants were recruited
from 27 U.S. study sites and were ex-
cluded if they had conditions that would
impair their ability to participate or took
certain medicines, including thiazide di-
uretics and -blockers (16). All partici-
pants gave informed consent and signed
documents approved by the institutional
review board at each center. Eligible par-
ticipants received standard advice on a
healthy diet and physical activity and
were randomly assigned to one of three
additional interventions (intensive life-
style intervention versus metformin ver-
sus matching placebo).
Measurements and laboratory tests
Development of diabetes was determined
by an annual OGTT or by a semiannual
fasting plasma glucose level with confir-
mation by a second test, using the criteria
of the American Diabetes Association (21)
and the World Health Organization (17).
Urinary albumin excretion was estimated
from a morning fasting spot urine sample
by the urinary albumin-to-urinary creati-
nine ratio (i.e., milligrams of albumin per
gram of creatinine). Urinary albumin was
measured using Behring reagents on the
BN II nephelometer (Dade Behring, Deer-
field, IL) (interassay coefficient of varia-
tion [CV] 4.4% and intra-assay CV 4.3%).
Microalbuminuria was defined using
standard criteria as ACR between 30 and
300 mg/day, whereas macroalbuminuria
was defined as ACR300 mg/day. Serum
and urinary creatinine concentrations
were measured using Roche reagents on
the Hitachi 917 autoanalyzer (Boehringer
Mannheim, Mannheim, Germany) (se-
rum creatinine: interassay CV 3.5% and
intra-assay CV 3.2%; urinary creatinine:
Table 1—Baseline characteristics by quartile of ACR
Characteristics
Quartiles of ACR Correlation
coefficient P value*1 2 3 4
n 797 797 797 797
ACR (mg/g) 3.0 (0.7–3.7) 4.6 (3.7–5.5) 7.1 (5.5–9.7) 16.5 (9.7–1578)
Age (years) 50.0  10.6 50.3  10.3 50.7  10.5 51.5  11.1 0.04 0.02
Sex (% male) 41.3 34.1 25.5 28.4 — 0.01
Race (as row %) — 0.77
White 23.7 25.3 26.9 24.1
Black 31.4 20.2 21.8 26.7
Hispanic 23.0 26.6 25.9 24.5
Native American 23.0 30.3 20.4 26.3
Asian 22.4 22.4 30.6 24.7
Family history of diabetes (% yes) 70.8 70.9 68.3 68.4 — 0.94
History of gestational diabetes (% yes) 16.0 15.8 15.3 17.2 — 0.78
BMI (kg/m2) 33  6 34  7 34  6 35  7 0.09 0.01
Waist circumference (cm) 105  13 104  15 104  14 107  15 0.07 0.01
Fasting glucose (mg/dl) 107  9 106  8 106  8 107  8 0.01 0.94
2-h OGTT (mg/dl) 165  17 164  17 164  17 166  17 0.03 0.06
Fasting insulin (pmol/l) 25  13 26  14 27  16 29  17 0.08 0.01
A1C (%) 5.9  0.5 5.9  0.5 5.9  0.5 6.0  0.5 0.05 0.01
Homeostasis model assessment of insulin
resistance
6.6  3.6 7.0  3.9 7.0  4.4 7.7  4.7 0.07 0.01
Systolic blood pressure (mmHg) 120  14 122  14 124  14 129  16 0.2 0.01
Diastolic blood pressure (mmHg) 77  9 77  9 78  9 81  10 0.1 0.01
Smoking (%) 7.9 5.5 5.5 8.8 — 0.27
Serum creatinine (mg/dl) 0.83  0.17 0.78  0.17 0.76  0.16 0.76  0.18 0.16 0.01
Total cholesterol (mg/dl) 203  36 202  37 205  36 204  37 0.02 0.21
Triglycerides (mg/dl) 160  89 164  91 160  92 171  111 0.01 0.47
Medication usage (%)
ACE inhibitor 6.1 6.5 8.3 10.2 — 0.01
Angiotensin receptor blocker 1.0 0.9 1.0 1.0 — 0.91
Calcium channel blocker 5.5 5.1 6.9 12.0 — 0.01
Diuretic† 1.8 2.0 1.8 1.9 — 0.50
Study randomization (%) — 0.75
Lifestyle 32.4 34.8 31.5 34.9
Metformin 35.9 30.2 32.7 33.4
Placebo 31.7 35.0 35.8 31.7
Data are median (25th–75th quartile) or means SD unless indicated otherwise. *P values are calculated using Spearman’s rank correlation for continuous variables
(e.g., age or BMI). For categorical variables (e.g., sex or race), P values are from ANOVA tests using base 2 logarithm of urinary albumin excretion. †Nine of the 60
participants taking diuretics at baseline were taking thiazides, which is a protocol violation.
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interassay CV 1.8% and intra-assay CV
1.2%).
Immunoreactive insulin was mea-
sured in plasma. Measurement methods
for glucose and insulin have been pub-
lished previously (18). Insulin secretion
and sensitivity were expressed using glu-
cose and insulin measured in conven-
tional units (milligrams per deciliter and
microunits per milliliter, respectively).
Insulin secretion was measured using the
corrected insulin response (100 30-
min insulin)/(30-min glucose  [30-min
glucose 70 mg/dl]) (19). Insulin sensi-
tivity was measured using the insulin sen-
sitivity index, which is 22.5/(fasting
insulin  [fasting glucose/18.0]), the re-
ciprocal of which is the homeostasis
model assessment of insulin resistance
(HOMA-IR) (20). Baseline demographic
and anthropometric (i.e., BMI measured
as weight in kilograms divided by height
in meters and waist circumference) data
were also measured.
Statistical methods
Because of its skewed distribution, ACR
was analyzed both as a categorical (i.e., by
quartiles) and as a continuous (i.e., after
base 2 logarithm transformation) vari-
able. Baseline characteristics were de-
scribed by means  SD for continuous
variables and percentages for categorical
variables. Spearman’s correlation coeffi-
cients between continuous variables and
ACR were reported. For categorical vari-
ables, ANOVA was used to identify differ-
ences in the base 2 logar i thm-
transformed ACR. Because a significant
interaction (P 0.05) was noted between
treatment group and incident diabetes
when ACR was divided into quartiles (but
not when it was examined as a continuous
variable after base 2 logarithm transfor-
mation), the former analysis was stratified
by treatment arm. Cox proportional haz-
ards models were used to evaluate the
association between ACR and risk of de-
veloping diabetes by both univariate
and multivariate means. The first mul-
tivariate model adjusted for the demo-
graphic factors age, sex, and race/
ethnicity alone, whereas the second
included demographics with the time-
dependent covariates exercise and
weight loss as well as baseline charac-
teristics that were associated with ACR
in a statistically significant manner (at
the 0.05 level). All analyses were per-
formed using SAS (SAS Institute, Cary,
NC). Nominal P values are presented
without adjustment for multiplicity of
testing.
RESULTS
Descriptive data
The DPP randomly assigned 3,234 partic-
ipants to one of three treatment arms (pla-
cebo, metformin, or lifestyle). Our
analysis included only the 3,188 individ-
uals with ACR data at baseline. The dis-
tribution of baseline ACR was highly
skewed at the upper end. Overall, 2,997
participants (94%) had ACR levels below
the microalbuminuria cutoff point of 30
mg/g, and only 14 (0.4%) had macroalbu-
minuria (ACR level300 mg/g). The me-
dians and ranges of ACR within quartiles
are shown in Table 1.
The cross-sectional association be-
tween baseline characteristics and ACR is
shown in Table 1. ACR was positively as-
sociated with age and markers of adipos-
ity and insulin secretion and resistance,
blood pressure, and use of antihyperten-
sive agents with antiproteinuric effects
and was inversely related to male sex and
serum creatinine, both of which influence
urinary excretion of creatinine, the de-
nominator in the ACR. Race/ethnicity,
prior gestational diabetes, family history
of diabetes, serum lipids, and smoking
were not significantly associated with
ACR.
ACR and development of diabetes
The 3,188 participants were followed for
a mean of 3.2 years (range 0–5.0 years),
during which 674 (21%) developed dia-
betes. A test of heterogeneity revealed a
significant interaction between ACR,
treatment group, and diabetes risk, so the
analysis was stratified by treatment group.
Table 2 shows HRs for incident diabetes
by ACR quartile for the unadjusted and
fully adjusted stratified models. No con-
sistent pattern was seen for either ad-
justed or unadjusted models or with a
model adjusting for demographic charac-
teristics alone (data not shown). When
ACR was examined as a continuous vari-
able, the unadjusted model showed a 7%
increase in incident diabetes with every
doubling of ACR (hazard ratio [HR] 1.07
[95% CI 1.0–1.1]), but statistical signifi-
cance was lost (0.98 [0.91–1.06]) when
the model was fully adjusted for the co-
variates baseline age, sex, race, BMI, waist
circumference, fasting insulin, insulin
sensitivity/secretion, systolic and diastolic
blood pressure, serum creatinine, and
ACE inhibitor and calcium channel
blocker use and for time-dependent
changes in weight and physical activity.
To test the possibility that examining
quartiles of ACR may not have been sen-
sitive enough to reveal an association be-
tween incident diabetes and ACR at its
higher range (e.g., microalbuminuria), as
suggested by other studies (10,11), HRs
were examined after each DPP treatment
cohort was separately divided into 10
equal groups by ACR (100 participants/
group) (Fig. 1). No consistent pattern
was observed between ACR and incident
diabetes before or after full adjustment
for covariates in the highest decile, in
which 191 of 318 subjects had micro- or
macroalbuminuria.
CONCLUSIONS— Identifying a sim-
ple, safe, and inexpensive tool to improve
Table 2—Relative hazards for developing diabetes in the DPP by quartile of baseline ACR
Study arm
HRs (95% CI) for quartile of ACR
1
(0.7–3.7 mg/g)
2
(3.7–5.5 mg/g)
3
(5.5–9.7 mg/g)
4
(9.7–1,578 mg/g)
Placebo (n  1,070)
Unadjusted 1.0 0.66 (0.47–0.93) 0.81 (0.58–1.12) 1.01 (0.72–1.37)
Adjusted* 1.0 0.51 (0.33–0.79) 0.68 (0.44–1.03) 0.76 (0.50–1.15)
Lifestyle (n  1,064)
Unadjusted 1.0 1.64 (0.99–2.72) 1.57 (0.93–2.64) 1.85 (1.12–3.06)
Adjusted* 1.0 1.56 (0.83–2.93) 1.15 (0.58–2.29) 1.62 (0.84–3.14)
Metformin (n  1,054)
Unadjusted 1.0 1.21 (0.82–1.78) 1.13 (0.76–1.66) 1.39 (0.96–2.03)
Adjusted* 1.0 1.21 (0.76–1.93) 1.03 (0.64–1.64) 0.98 (0.60–1.58)
Data are median (range). ACR is calculated as milligrams of albumin/grams of creatinine. *Adjusted for
baseline: age, sex, race, BMI, waist circumference, fasting insulin, insulin sensitivity/secretion, systolic and
diastolic blood pressure, serum creatinine, and ACE inhibitor and calcium channel blocker use. Also ad-
justed are time-dependent changes in weight and physical activity.
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prediction of future diabetes would be an
important public health achievement, es-
pecially in light of the ongoing diabetes
pandemic. Preliminary results from sev-
eral observational studies raise the possi-
bility that low levels of ACR could play
such a role, with further (indirect) evi-
dence being that proteinuria-reducing
antihypertensive agents are associated
with a reduced risk of incident diabetes
(13,14). However, in the present study,
the largest study of pre-diabetic individu-
als to date, we did not find that ACR had
any independent predictive value.
Our study hypothesis was not neces-
sarily dependent upon a causal link be-
tween increasing ACR and onset of
diabetes. For example, one possible
premise is that exposure to levels of gly-
cemia below what is conventionally con-
sidered pathological induces changes in
renal handling of urinary albumin, which in
turn would lead to increased ACR. Alterna-
tively, increased ACR could simply be one
of a number of early, organ-specific mani-
festations of insulin resistance that herald
the onset of diabetes. Regardless, we felt it
important to test this hypothesis, especially
given prior findings.
Results from previous observational
studies have supported an association be-
tween urinary albumin excretion and in-
cident diabetes. In a longitudinal study of
2,205 American Indians, ACR of 30
mg/day (i.e., microalbuminuria or mac-
roalbuminuria) predicted incident diabe-
tes over an average of 4 years of follow-up
in a combined group of men with normal
or IGT (odds ratio 2.19 [95% CI 1.48–
3.21]) and women with baseline IGT only
(2.69 [1.41–5.21]) (11). A prospective,
community-based Dutch study of 5,654
individuals with normal or impaired glu-
cose tolerance found a stepwise increase
in the 4-year risk of incident diabetes by
baseline urinary albumin excretion as
measured by 24-h urine collections (ter-
tile 1, 6.9 mg/kg, 1.8%; tertile 2, 6.9–
12.4 mg/kg, 2.3%; tertile 3, 12.4 mg/
kg, 5.8%; P  0.001) (12). Results were
relatively unchanged when individuals
with baseline IGT were excluded from the
analysis. Mykka¨nen et al. (10) observed a
significantly higher proportion of base-
line microalbuminuria (44.4% vs. 30.4%,
P  0.017) in elderly Finns who devel-
oped diabetes after 3.5 years of follow-up
(compared with those who did not), al-
though there was no actual difference in
mean ACR between groups. In this study,
the increased odds of developing diabetes
were no longer statistically significant af-
ter adjustment for fasting plasma glucose
and insulin.
Our study contributes new informa-
tion that has been lacking in several im-
portant ways. First, our cohort was
composed exclusively of individuals who
were at high risk of developing diabetes
on the basis of elevated fasting glucose
and IGT plus overweight or obesity (for
the majority). Because our sample size
was far larger than all the IGT subgroups
from the previously mentioned studies
combined, it is unlikely that our negative
findings were related to insufficient statis-
tical power. Interestingly, despite their el-
evated risk for diabetes, the great majority
of our cohort did not have microalbumin-
uria. Second, we analyzed ACR through-
out its continuous range, avoiding
artificial cutoff values, such as microalbu-
minuria, that could limit its descriptive
utility (6). On the other hand, the DPP
included very few subjects with micro- or
macroalbuminuria, which could have re-
Figure 1—HRs for incident diabetes in DPP by baseline urinary albumin creatinine ratio. Placebo
group (A), lifestyle group (B), metformin group (C). », unadjusted data;, adjusted data.
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duced the power to show an association
in these ranges and the generalizability of
our results. Indeed, the predictive power
of ACR could have been obscured by the
increased risk for development of diabe-
tes present in the DPP cohort at baseline.
The fact that ACR was so closely associ-
ated with insulin or glycemic parameters
supports this hypothesis. In addition, we
excluded individuals with chronic kidney
disease, further reducing generalizability,
and measured ACR only once at baseline.
ACR can be affected by diet, physical ac-
tivity, and other habits, which may have
introduced some variability into our find-
ings, although this would be limited
somewhat by the uniform collection cri-
terion (i.e., fasting morning sample). Fi-
nally, major differences between the
DPP and prior studies were the ethni-
cally and culturally diverse cohort and
the fact that we detected early diabetes
by annual or semiannual surveillance
glucose tolerance tests using accepted
criteria (17,21), thus reducing the like-
lihood that ACR reflected prior expo-
sure to severe hyperglycemia.
The study hypothesis was based on
the presumption that subtle damage oc-
curs within the kidney in the pre-diabetic
state—whether from chronic exposure to
abnormal glycemia that is below the for-
mal threshold for diabetes, elevated intra-
renal blood pressure, or oxidative stress
(22), among other causes—that manifests
itself as elevated ACR. ACR, as a subtle
marker of incipient damage, could in turn
herald the onset of diabetes. Although we
did not confirm such a relationship, this
does not exclude the possibility that ACR
can predict hard outcomes in this popu-
lation, as it has in others.
In summary, in a population of sub-
jects at elevated risk for diabetes, ACR be-
low the microalbuminuria range does not
predict incident diabetes.
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